Q2 2016 13F Holders as of 6/30/2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
115M
-
Number of holders
-
84
-
Total 13F shares, excl. options
-
25.3M
-
Shares change
-
+7.08M
-
Total reported value, excl. options
-
$428M
-
Value change
-
+$112M
-
Put/Call ratio
-
107.5
-
Number of buys
-
63
-
Number of sells
-
-20
-
Price
-
$16.89
Significant Holders of Coherus Oncology, Inc. - Common Stock (CHRS) as of Q2 2016
97 filings reported holding CHRS - Coherus Oncology, Inc. - Common Stock as of Q2 2016.
Coherus Oncology, Inc. - Common Stock (CHRS) has 84 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.3M shares
of 115M outstanding shares and own 21.93% of the company stock.
Largest 10 shareholders include FMR LLC (6.4M shares), Kohlberg Kravis Roberts & Co. L.P. (3.06M shares), WELLINGTON MANAGEMENT GROUP LLP (2.14M shares), JPMORGAN CHASE & CO (1.88M shares), BlackRock Fund Advisors (1.27M shares), VANGUARD GROUP INC (1.01M shares), TIAA CREF INVESTMENT MANAGEMENT LLC (725K shares), CITADEL ADVISORS LLC (676K shares), VHCP Management, LLC (611K shares), and Cormorant Asset Management, LLC (576K shares).
This table shows the top 84 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.